Federal Register Notice: FDA has determined the regulatory review period for Pharmacia & Upjohn’s Aromasin is 3,153 days for the extension of a patent that claims that human drug product. Aromasin (exemestane) is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy. To view this notice, click here.
